Fig. 3From: Risk of Hepatocellular Carcinoma with Glucagon-like Peptide-1 receptor agonist treatment in patients: a systematic review and meta-analysisSubgroup analysis showing pooled HRs for HCC risk with GLP-1 RA vs. no GLP-1 RA and insulin comparatorsBack to article page